Clinical Trial Detail

NCT ID NCT02710396
Title Genetic Predictors of Benefit to Pembrolizumab
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Columbia University
Indications

head and neck cancer

bladder urothelial carcinoma

esophagus squamous cell carcinoma

lung non-small cell carcinoma

Therapies

Carboplatin + Pembrolizumab + Pemetrexed Disodium

Pembrolizumab

Carboplatin + Nab-paclitaxel + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST